PENG Block for Total Hip Arthroplasty
CompletedPhase 4NCT05944380
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This randomized, double-blinded, placebo-controlled trial seeks to evaluate the efficacy of the pericapsular nerve group block on postoperative rehabilitation.
Study details
- Official title
- Periarticular Nerve Group (PENG) Block for Postoperative Rehabilitation in Total Hip Arthroplasty: a Randomized Controlled Trial
- Conditions
- Hip Osteoarthritis
- Hip Arthropathy
- Hip Disease
- Hip Pain Chronic
- Interventions
- Drug: Ropivacaine 0.5% Injectable Solution
- Drug: 0,9% normal saline
- Sponsor
- Poznan University of Medical Sciences
- Start date
- 2020-06-16
- Primary completion
- 2022-06-23
- Sex
- All
- Age range
- from 18 Years to 100 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- Poland
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients \> 18 years old undergoing unilateral total hip arthroplasty Exclusion Criteria: * refusal to participate * \< 18 yo * Chronic opioid use * localized infection
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05944380